PMID- 37621311
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230826
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 14
DP  - 2023
TI  - Effectiveness and safety of Lacosamide therapy for children with focal epilepsy: 
      a real world study.
PG  - 1186768
LID - 10.3389/fphar.2023.1186768 [doi]
LID - 1186768
AB  - Objectives: To compare the effectiveness and safety of the new antiepileptic 
      drug, lacosamide (LCM) with Levetiracetam, for the treatment of focal epilepsy in 
      children. Methods: This study was a cohort study. Children with focal epilepsy 
      who received LCM or Levetiracetam treatment in West China Second Hospital of 
      Sichuan University were recruited and followed up for 12 months. Changes in the 
      frequency of epilepsy, 50% and 75% responder rates, and seizure freedom rates 
      from baseline to the maintenance period and adherence score were assessed. In 
      addition, adverse events (AEs) were recorded. Results: 92 patients completed the 
      study, and were divided into two groups: LCM (n = 46) and Levetiracetam (n = 46). 
      Participants were aged from 2 to 16.3 years, with a mean epilepsy duration of 
      2.57 years. The average maintenance dose of LCM was 5.03 +/- 1.91 mg/kg/d after the 
      titration period. There was no significant difference between the two groups in 
      terms of the mean seizure frequency during subsequent visits at 1, 3,6, 9, 12 
      months. There was significant difference between the two groups in terms of the 
      50% responder rate at 6 months. No serious AEs were reported in both groups. The 
      vast majority of patients had good adherence (adherence score = 4) in the LCM 
      group. Conclusion: LCM is effective as adjunctive therapy in children with 
      epilepsy and has good safety, tolerability and adherence. Large sample size 
      studies with long-term follow-up are needed in the future to comprehensively 
      evaluate the use of LCM in children. Clinical Trial Registration: 
      [https://www.chictr.org.cn/showproj.html?proj=41041], identifier 
      [ChiCTR1900024507].
CI  - Copyright (c) 2023 Yang, Liu, Peng, Zhang and Yu.
FAU - Yang, Chunsong
AU  - Yang C
AD  - Department of Pharmacy, West China Second University Hospital, Sichuan 
      University, Chengdu, China.
AD  - Evidence-Based Pharmacy Center, West China Second University Hospital, Sichuan 
      University, Chengdu, China.
AD  - NMPA Key Laboratory for Technical Research on Drug Products in Vitro and in Vivo 
      Correlation, Chengdu, China.
AD  - Key Laboratory of Birth Defects and Related Diseases of Women and Children, 
      Sichuan University, Ministry of Education, Chengdu, China.
FAU - Liu, Zheng
AU  - Liu Z
AD  - Department of Pharmacy, West China Second University Hospital, Sichuan 
      University, Chengdu, China.
AD  - Evidence-Based Pharmacy Center, West China Second University Hospital, Sichuan 
      University, Chengdu, China.
AD  - NMPA Key Laboratory for Technical Research on Drug Products in Vitro and in Vivo 
      Correlation, Chengdu, China.
AD  - Key Laboratory of Birth Defects and Related Diseases of Women and Children, 
      Sichuan University, Ministry of Education, Chengdu, China.
AD  - West China School of Medicine, Sichuan University, Chengdu, China.
FAU - Peng, Yuxuan
AU  - Peng Y
AD  - West China School of Pharmacy, Sichuan University, Chengdu, China.
FAU - Zhang, Lingli
AU  - Zhang L
AD  - Department of Pharmacy, West China Second University Hospital, Sichuan 
      University, Chengdu, China.
AD  - Evidence-Based Pharmacy Center, West China Second University Hospital, Sichuan 
      University, Chengdu, China.
AD  - NMPA Key Laboratory for Technical Research on Drug Products in Vitro and in Vivo 
      Correlation, Chengdu, China.
AD  - Key Laboratory of Birth Defects and Related Diseases of Women and Children, 
      Sichuan University, Ministry of Education, Chengdu, China.
AD  - Chinese Evidence-based Medicine Center, West China Hospital, Sichuan University, 
      Chengdu, China.
FAU - Yu, Dan
AU  - Yu D
AD  - Key Laboratory of Birth Defects and Related Diseases of Women and Children, 
      Sichuan University, Ministry of Education, Chengdu, China.
AD  - Department of Children's Genetic Endocrinology and Metabolism, West China Second 
      University Hospital, Sichuan University, Chengdu, China.
LA  - eng
PT  - Journal Article
DEP - 20230809
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC10446477
OTO - NOTNLM
OT  - children
OT  - effectiveness
OT  - focal-onset epilepsy
OT  - lacosamide
OT  - safety
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/08/25 06:42
MHDA- 2023/08/25 06:43
PMCR- 2023/08/09
CRDT- 2023/08/25 03:44
PHST- 2023/03/15 00:00 [received]
PHST- 2023/07/28 00:00 [accepted]
PHST- 2023/08/25 06:43 [medline]
PHST- 2023/08/25 06:42 [pubmed]
PHST- 2023/08/25 03:44 [entrez]
PHST- 2023/08/09 00:00 [pmc-release]
AID - 1186768 [pii]
AID - 10.3389/fphar.2023.1186768 [doi]
PST - epublish
SO  - Front Pharmacol. 2023 Aug 9;14:1186768. doi: 10.3389/fphar.2023.1186768. 
      eCollection 2023.